Noetik

Noetik is an AI-native biotechnology company building foundation models of human cancer biology to discover precision immunotherapies. It pairs one of the world's largest proprietary spatial-omics datasets - hundreds of millions of spatially resolved tumor and immune cells - with a high-throughput in vivo CRISPR Perturb-Map platform to train multimodal virtual cell models like OCTO-VC. These models simulate gene expression, cell states, and tumor-immune interactions, letting researchers find drug targets and predict patient response computationally. Founded in 2022 by former Recursion leaders Ron Alfa and Jacob Rinaldi, Noetik has raised roughly $62M and licenses its models to pharma, including an anchor partnership with GSK.